Special Feature on     

Published: Mar 31, 2023
Updated: Mar 31, 2023

Indoco Remedies

Partner of choice to global pharma

Indoco is a fully integrated, research-oriented pharmaceutical company with a presence in 55 countries. The company’s turnover is $ 198 million and it has a human capital of 6,000 employees, including over 300 skilled scientists and field staff who are the strength of the organization.

The company has 9 manufacturing facilities, 6 for Finished Dosages and 3 for APIs, supported by a state-of-the-art R&D facility in Navi Mumbai and a clinical research organization (CRO) in Hyderabad. The facilities have been approved by most global regulatory authorities, including USFDA and UK-MHRA.

Unlike most Indian pharmaceutical companies who commenced their business with APIs and then forward integrated into formulations, Indoco started with Finished Dosages and then forayed into the API business as a backward integrated initiative to support its captive demand.

STRONG BRANDS

Indoco exports a variety of products to regulated and emerging markets, including the US and EU. The company has tie-ups with large generic companies and works in close coordination with its customers to leverage core competencies. Indoco’s branded formulations are promoted and distributed across India and in the emerging markets of South East Asia, Africa, Latin America and CIS countries. With several legacy brands in India and a fast-growing ethical business in the emerging markets, Indoco is a partner of choice for several large pharmaceutical companies across the globe.

On the manufacturing front, Indoco’s core strength lies in the development of complex sterile formulations. Indoco has several firsts in filing ANDAs and a strong development pipeline to support the company’s growth. Its focus is to develop differentiated generics and innovative speciality products to strengthen its global specialty pipeline, a key determinant of future growth. R&D is crucial for the pharma industry to be able to offer better products to fulfil the unmet needs of patients. Indoco has a state-of-the-art R&D centre in Navi Mumbai that spans over 100,000 square feet and is dedicated to the future of modern medicine.

The company’s R&D team develops non-infringing processes for APIs, formulations and various dosage forms like Immediate Release Tablets, Capsules, Multi-Unit Pellet Systems (MUPS), Pulsatile Drug Delivery Systems, Sterile Ophthalmic Ointments, Ophthalmic Gels, Suspensions and Solutions, Extended Release Tablets with matrix technology, complex ophthalmic products like emulsions and nano suspensions, as well as a range of injectable solutions, suspensions and depot based long-acting injectables.

R&D STRENGTH

In addition to R&D and manufacturing excellence, Indoco also offers various services to pharmaceutical companies within India and abroad. Its CRO, based in Hyderabad, provides clinical trial solutions, including bioavailability and bioequivalence (BA/BE)/ Phase I/Phase II studies. The CRO is a USFDA-inspected clinical research facility and is spread over a 40,000 sq ft area, with 140 beds and staffed by experienced professionals. The CRO has successfully completed more than 500 studies in multiple therapeutic areas such as cardiovascular, diabetes, oncology, anti-retroviral and antacids.

The Indoco Analytical Solutions (IAS) division is USFDA-approved and based at Rabale, Navi Mumbai. The division serves customers for their analytical research needs, utilizing state-of-the-art instruments and infrastructure through a team of experts in the field. The XTEND division offers end-to-end engineering and consulting services for all phases of project development, right from project design to validation. XIDEL has been providing these services to the pharmaceutical and API sectors for the past 15 years and has completed several projects.

It was the philosophy of the founder, the late Govind Ramnath Kare, to give back to society in proportion to what one receives from it. This philosophy has always been at the forefront of CSR initiatives at Indoco. The company works actively towards the betterment of society and helps the underprivileged across India and overseas through its CSR initiative, ‘Sumati Sangopan’. In the areas of health, education, sanitation and environment, Indoco reaches out to the needy with a significant focus on the welfare of women, the aged and children, thereby creating better lives for a brighter future. ESG (Environmental, Social and Governance) is a framework to map out a company’s impact on the world. The company’s core corporate responsibility is to practice its corporate values through a commitment to grow in a socially and environmentally responsible way, while meeting the interests of its stakeholders.